MDxHealth (NASDAQ:MDXH) Upgraded by Wall Street Zen to Hold Rating

Key Points

• MDxHealth has been upgraded to a "hold" rating by Wall Street Zen, while Craig Hallum initiated coverage with a "buy" rating and a target price of $8.00.
• The stock opened at $3.55, with a market capitalization of $167.87 million and a twelve-month price range of $1.35 to $3.81.
• In terms of earnings, MDxHealth reported a loss of ($0.15) EPS for the last quarter, missing estimates, and has set a projection of -0.150 to -0.150 EPS for Q2 2025.

Wall Street Zen upgraded shares of MDxHealth (NASDAQ:MDXH - Free Report) to a hold rating in a report published on Saturday.

Separately, Craig Hallum began coverage on MDxHealth in a research report on Thursday, July 17th. They issued a "buy" rating and a $8.00 price objective for the company. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $7.00.

MDxHealth Stock Down 1.7%

MDXH traded down $0.06 on Friday, reaching $3.53. The company's stock had a trading volume of 179,258 shares, compared to its average volume of 159,327. MDxHealth has a fifty-two week low of $1.35 and a fifty-two week high of $3.81. The company has a quick ratio of 1.22, a current ratio of 1.31 and a debt-to-equity ratio of 13.81. The company has a market capitalization of $166.93 million, a price-to-earnings ratio of -4.01 and a beta of 1.49. The stock has a 50 day moving average of $2.69 and a two-hundred day moving average of $2.09.

MDxHealth (NASDAQ:MDXH - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The business had revenue of $26.60 million for the quarter, compared to analyst estimates of $26.60 million. MDxHealth had a negative return on equity of 374.98% and a negative net margin of 34.98%. MDxHealth has set its Q2 2025 guidance at -0.150--0.150 EPS. As a group, analysts forecast that MDxHealth will post -1.15 EPS for the current fiscal year.

Institutional Investors Weigh In On MDxHealth

A number of large investors have recently bought and sold shares of the business. AWM Investment Company Inc. boosted its stake in shares of MDxHealth by 10.6% during the 1st quarter. AWM Investment Company Inc. now owns 5,221,282 shares of the company's stock worth $7,414,000 after acquiring an additional 499,992 shares in the last quarter. Northern Trust Corp bought a new position in MDxHealth in the 4th quarter worth $1,033,000. Perkins Capital Management Inc. boosted its holdings in MDxHealth by 20.1% during the first quarter. Perkins Capital Management Inc. now owns 1,181,475 shares of the company's stock valued at $1,678,000 after acquiring an additional 198,000 shares during the period. Delta Investment Management LLC grew its holdings in MDxHealth by 459.1% in the 1st quarter. Delta Investment Management LLC now owns 190,100 shares of the company's stock valued at $270,000 after buying an additional 156,100 shares during the last quarter. Finally, FreeGulliver LLC acquired a new position in shares of MDxHealth during the second quarter worth approximately $273,000.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.